What does Scinai Immunotherapeutics do?

Scinai Immunotherapeutics Ltd. is a biopharmaceutical company based in Jerusalem, Israel, with over 20 years of expertise in recombinant protein process development and cGMP manufacturing. The company operates two main business units: an in-house R&D division and a boutique Contract Development and Manufacturing Organization (CDMO). The R&D division focuses on creating biological therapeutics for inflammation and immunology, particularly targeting autoimmune and infectious diseases. Their innovative technology platform utilizes nanosized VHH antibodies, which are unique alpaca-derived antibody fragments. This platform aims to address significant medical needs, with initial projects centered on conditions like psoriasis and asthma. The CDMO unit offers comprehensive contract manufacturing and development services to biotech companies, including analytical method development and clinical cGMP manufacturing. It specifically caters to biotech startups working with recombinant proteins, providing flexible and cost-effective solutions that comply with EMA and FDA standards. Scinai is listed on NASDAQ under the ticker symbol SCNI and supports biotech innovators throughout the drug development process.